Ann Cahill

838 total citations
12 papers, 640 citations indexed

About

Ann Cahill is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ann Cahill has authored 12 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 5 papers in Molecular Biology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ann Cahill's work include Acute Myeloid Leukemia Research (10 papers), Acute Lymphoblastic Leukemia research (5 papers) and Cancer therapeutics and mechanisms (3 papers). Ann Cahill is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Acute Lymphoblastic Leukemia research (5 papers) and Cancer therapeutics and mechanisms (3 papers). Ann Cahill collaborates with scholars based in United States, France and Serbia. Ann Cahill's co-authors include Mario Sznol, Caroline Clairmont, Joseph A. Kuhn, Robert Cavagnolo, Neil Senzer, Casey Cunningham, John Nemunaitis, Craig E. Litz, Francis J. Giles and Susan O’Brien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Ann Cahill

12 papers receiving 628 citations

Peers

Ann Cahill

BIOTE

HEMAT

ONCOL

Cihangir Duy United States

Christine Bryson United Kingdom

Sanjay Shah United States

Kiran Khandke United States

Marianne Mikaelsson Sweden

Xiamei Zhang United States

Natalia Oganesyan United States

Artur Mitterer Austria

Maria L. Amaya United States

Sylvie Cochet France

Cihangir Duy United States

Ann Cahill

520 ×1.9

61 ×0.3

BIOTE

225 ×1.2

HEMAT

139 ×0.9

ONCOL

28 ×0.2

Citations per year, relative to Ann Cahill Ann Cahill (= 1×) peers Cihangir Duy

Countries citing papers authored by Ann Cahill

Since Specialization

Citations

This map shows the geographic impact of Ann Cahill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Cahill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Cahill more than expected).

Fields of papers citing papers by Ann Cahill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Cahill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Cahill. The network helps show where Ann Cahill may publish in the future.

Co-authorship network of co-authors of Ann Cahill

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Cahill. A scholar is included among the top collaborators of Ann Cahill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Cahill. Ann Cahill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Rizzieri, David A., Samantha LoRusso, William Tse, et al.. (2010). Phase I Study of Temozolomide and Laromustine (VNP40101M) in Patients With Relapsed or Refractory Leukemia. Clinical Lymphoma Myeloma & Leukemia. 10(3). 211–216. 9 indexed citations

Giles, Francis J., Norbert Vey, Daniel J. DeAngelo, et al.. (2009). Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 114(19). 4027–4033. 37 indexed citations

Schiller, Gary J., Susan O’Brien, Arnaud Pigneux, et al.. (2009). Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia. Journal of Clinical Oncology. 28(5). 815–821. 58 indexed citations

Yee, Karen, Jörge E. Cortes, Alessandra Ferrajoli, et al.. (2006). Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leukemia Research. 30(7). 813–822. 41 indexed citations

Badruddoja, Michael, Kara Penne, Annick Desjardins, et al.. (2006). Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme1. Neuro-Oncology. 9(1). 70–74. 11 indexed citations

Menzin, Joseph, et al.. (2006). Effects of Initial Treatment on Survival among Elderly AML Patients: Findings from the SEER-Medicare Database.. Blood. 108(11). 1973–1973. 12 indexed citations

Giles, Francis J., Wendy Stock, Norbert Vey, et al.. (2006). A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without Cloretazine® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood. 108(11). 1970–1970. 3 indexed citations

Rizzieri, David A., Judith E. Karp, Norbert Vey, et al.. (2006). Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia. Journal of Clinical Oncology. 25(1). 25–31. 64 indexed citations

Giles, Francis J., Srđan Verstovšek, Deborah A. Thomas, et al.. (2005). Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. Clinical Cancer Research. 11(21). 7817–7824. 28 indexed citations

10.

Giles, Francis J., Deborah A. Thomas, Guillermo Garcia‐Manero, et al.. (2004). A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia. Clinical Cancer Research. 10(9). 2908–2917. 37 indexed citations

11.

Giles, Francis J., Paula M. Fracasso, Hagop M. Kantarjian, et al.. (2003). Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research. 27(12). 1077–1083. 79 indexed citations

12.

Nemunaitis, John, Casey Cunningham, Neil Senzer, et al.. (2003). Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Therapy. 10(10). 737–744. 261 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact